Improving antibody discovery using machine learning techniques
REPTOR: accelerating antibody discovery and improving hits with machine learning
This study is working on using smart computer programs to help find better antibody treatments for COVID-19 faster, so patients can get access to new and effective options more quickly.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abterra Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11322291 on NIH RePORTER |
What this research studies
This research focuses on enhancing the discovery of antibody therapeutics by integrating advanced software that utilizes high-throughput sequencing data. By applying machine learning algorithms, the project aims to streamline the process of identifying effective antibodies from the immune responses of individuals, particularly in the context of the COVID-19 pandemic. The methodology involves analyzing large datasets to improve the success rate of antibody discovery and to refine existing antibody candidates. Patients may benefit from faster access to new and effective antibody treatments developed through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals who have recovered from COVID-19 and have a strong immune response.
Not a fit: Patients who are not recovering from COVID-19 or those without a significant immune response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the rapid development of more effective antibody therapies for various diseases, including those related to COVID-19.
How similar studies have performed: Other research has shown promise in using high-throughput sequencing and machine learning for antibody discovery, indicating that this approach could be effective.
Where this research is happening
San Diego, United States
- Abterra Biosciences, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Castellana, Natalie — Abterra Biosciences, INC.
- Study coordinator: Castellana, Natalie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.